LEADER 04061nam  22005415  450 
001 9910349377703321
005 20200701191144.0
010   $a3-030-20315-8
024 7 $a10.1007/978-3-030-20315-3
035   $a(CKB)4100000008707676
035   $a(MiAaPQ)EBC5831079
035   $a(DE-He213)978-3-030-20315-3
035   $a(PPN)238488799
035   $a(EXLCZ)994100000008707676
100   $a20190717d2019      u|         0
101 0 $aeng
135   $aurcnu||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aThrombosis and Hemostasis in Cancer /$fedited by Gerald Soff
205   $a1st ed. 2019.
210  1$aCham :$cSpringer International Publishing :$cImprint: Springer,$d2019.
215   $a1 online resource (211 pages)
225 1 $aCancer Treatment and Research,$x0927-3042 ;$v179
311   $a3-030-20314-X 
327   $aThrombosis and Hemostasis in Cancer. Scope of the Problem and Overview -- Pathophysiology 1. Mechanisms of Thrombosis in Cancer Patients -- Pathophysiology 3. The role of platelets in cancer biology -- The risk of thrombosis in cancer. Clinical factors & possible role of primary prophylaxis -- Biomarkers of cancer-associated thromboembolism -- Thrombotic Risk from Chemotherapy and Other Cancer Therapies -- Treatment of VTE In Cancer. Historical Perspective and evolving role of the DOACs -- Etiology and Management of Upper Extremity, Central line associated thrombosis -- Management of Thrombocytopenia In Cancer Patients -- Microangiopathy in Cancer. Causes, Consequences, and Management -- Thrombosis in the Philadelphia chromosome-negative Myeloproliferative Neoplasms -- Anticoagulation in the setting of primary and metastatic brain tumors -- Hemorrhage in the cancer patient. APML and other specific high risk situations.
330   $aIn this book, leaders in the field explore our current understanding of thrombosis and hemostasis in cancer and address key questions on the subject. Among the topics discussed are the mechanisms that cancers use to activate the coagulation system, and those by means of which an activated coagulation system can lead to more aggressive cancer growth. Clinical chapters examine the role of thrombosis prophylaxis and treatment, central line-associated thrombosis, and cancer-associated hemorrhage. Subsequent chapters deal with the management of chemotherapy-induced thrombocytopenia, anticoagulation in the presence of brain metastases, and other unique challenges in the interaction of thrombosis and hemostasis in cancer. It has been 150 years since Armand Trousseau first described the well-known association between cancer and an increased risk of thrombosis, which may be considered the first paraneoplastic syndrome ever identified. More recently, numerous studies have indicated that activation of the coagulation system by cancer not only increases the likelihood of thrombosis, but is also associated with a more aggressive cancer phenotype. By familiarizing readers with the latest developments in this complex and challenging field, the book offers a valuable resource for scientists and clinicians alike. .
410  0$aCancer Treatment and Research,$x0927-3042 ;$v179
606   $aOncology  
606   $aHematology
606   $aCancer research
606   $aOncology$3https://scigraph.springernature.com/ontologies/product-market-codes/H33160
606   $aHematology$3https://scigraph.springernature.com/ontologies/product-market-codes/H3307X
606   $aCancer Research$3https://scigraph.springernature.com/ontologies/product-market-codes/B11001
615  0$aOncology  .
615  0$aHematology.
615  0$aCancer research.
615 14$aOncology.
615 24$aHematology.
615 24$aCancer Research.
676   $a616.157
676   $a616.15
702   $aSoff$b Gerald$4edt$4http://id.loc.gov/vocabulary/relators/edt
906   $aBOOK
912   $a9910349377703321
996   $aThrombosis and Hemostasis in Cancer$91736031
997   $aUNINA